Adalimumab treatment of anti-TNF-naive patients with ulcerative colitis: Deep remission and response factors
Digestive and Liver Diseases Mar 20, 2018
Munoz-Villafran C, et al. - The purpose herein was to investigate the response to adalimumab in tumour necrosis factor (TNF)-antagonist-naive patients in the case of ulcerative colitis. The inference drawn was that adalimumab treatment of ulcerative colitis was effective. Yielded data appeared to be better in clinical practice and in patients naive to anti-TNF.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
